NewAmsterdam Pharma Company N.V. provided financial highlights for the first quarter ended March 31, 2023. The company have over 1,700 patients randomized in BROADWAY and over 3,400 patients randomized in PREVAIL and expect to complete enrollment in the middle of 2023 and the first quarter of 2024, respectively. The company believe that the strong enrollment have seen in each clinical trial, at a time when patients and investigators have the option of similar clinical trials using injectable drugs, reflects the significant unmet need for a potent oral therapy that can be used as an adjunct to maximally tolerated statin therapy to help patients achieve target low-density lipoprotein cholesterol (DL-C) levels.

Dr. Davidson continued, In addition, the company plan to announce data from multiple Phase 2 trials in the coming months. Clinical Development Updates: NewAmsterdam is developing obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximize statin therapy for high-risk cardiovascular disease patients. The company is currently conducting three pivotal Phase 3 clinical trials of obicetrapib: BROADWAY, evaluating the effect of obicetrapib on LDL-C levels in patients with HeFH as an adjunct to maximally tolerated lipid-lowering therapy; BROADWAY, evaluating the effects of obicetrapib On top of maximally tolerated lipid-lowering therapy in patients with HeFH and/or established atherosclerotic cardiovascular disease.

NewAmsterdam is also evaluating obicetrapib in a Phase 2a clinical trial in patients with early Alzheimer's disease and at least one copy of the apolipoprotein E4 mutation. Upcoming Potential Milestones: NewAmsterdam currently expects to achieve the following upcoming milestones: Present full data from the Phase 2 ROSE2 clinical trial testing the combination of obicetrapib and ezetimibe at the NLA Scientific Sessions, June 1-4, 2023 in Atlanta, GA.